| Literature DB >> 34164720 |
Thilini Nisansala1, Manjula Weerasekera1, Nilantha Ranasinghe2, Chamil Marasinghe3, Chandika Gamage4, Neluka Fernando1, Chinthika Gunasekara5.
Abstract
The immune response is hypothesized as an important factor in the disease outcome of leptospirosis. Exaggerated immune response may promote tissue damage that lead to severe disease outcome. In this study TNF, IL-10, sTNFR1 levels were measured among sixty-two hospitalized leptospirosis confirmed patients in Sri Lanka. Thirty-one serum samples from healthy individuals were obtained as controls. PCR-RFLP method was used to identify TNF gene polymorphisms and to determine their association with TNF expression and disease severity in leptospirosis. TNF (p = 0.0022) and IL-10 (p < 0.0001) were found to be significantly elevated in leptospirosis patients, while sTNFR1 (p < 0.0001) was significantly suppressed. TNF was not significantly elevated in patients with complications while the anti-inflammatory cytokine IL-10 was significantly elevated among patients with complications (p = 0.0011) and with mortality (p = 0.0088). The ratio of IL-10 to TNF was higher among patients with complications (p = 0.0008) and in fatal cases (p = 0.0179). No association between TNF gene polymorphisms and TNF expression was detected due to the low frequency of heterozygous and mutated genes present in this study population. Thus the findings of the study show that elevated levels of IL-10 in the acute phase of disease could lead to severe outcomes and a high IL-10/TNF ratio is observed in patients with complications due to leptospirosis.Entities:
Keywords: IL-10; Leptospirosis; TNF; TNF gene polymorphism; sTNFR1
Mesh:
Substances:
Year: 2021 PMID: 34164720 PMCID: PMC8221277 DOI: 10.1007/s00430-021-00714-5
Source DB: PubMed Journal: Med Microbiol Immunol ISSN: 0300-8584 Impact factor: 4.148
Fig. 1Confirmation of leptospirosis in 62 positive patients by MAT (n = 19), blood culture isolation (n = 2) and real time qPCR (n = 49). MAT was carried out against a panel of 15 reference Leptospira strains and a titer of ≥ 1:320 was considered as confirmatory based on the cut-off given by the national reference laboratory. Culture isolation of Leptospira was done by inoculating whole blood into semi solid EMJH medium. Real-time PCR (Biorad CFX96TM (Bio-Rad, USA)) based on EvaGreen technology was performed to detect pathogenic Leptospira spp, using secYIVF and secYIV. Seven confirmed patients were positive by both MAT and qPCR and one patient was positive by culture isolation and qPCR
Biochemical and haematological parameters of leptospirosis confirmed patients (n = 62)
| Haematological /biochemical parameter (normal range) | Total population ( | Patients with complications ( | Patients without complications ( | ||
|---|---|---|---|---|---|
| Median (IQR) | Range | ||||
| Haemoglobin (14.0–17.5 g/dl) | 11.60 (10.25–12.98) | 6.9–15.8 | 11.06 (9.9–12.2) | 12.07 (10.55–13.2) | 0.0353* |
| WBC (4000–11,000/mm3) | 10,700 (8,070–14,770) | 4,750–25,140 | 12,490 (8,830–16,080) | 9,210 (7,840–13,560) | 0.0072* |
| Neutrophils (2000–7000/mm3) | 9,301 (5,451) | 1,873–20,887 | 11,050 (7,919–13,959) | 7,762 (6,338–11,054) | 0.0015* |
| Lymphocytes (1000–3000/mm3) | 1,159 (710–2,052) | 286–7,080 | 896 (653–1,552) | 1,373 (782–2,776) | 0.0004* |
| Platelet count (150–450 *103/µl) | 91.5 (43.0–133.0) | 4.0–229.0 | 80.04 (25–118) | 108.20 (69–146.5) | 0.0436* |
| Serum creatinine (60–120 µmol/l) | 122.5 (96.28–191.6) | 55.69–1011 | 313.80 (150.10–538.75) | 99.15 (83.49–131.47) | < 0.0001* |
| Serum urea (2.5–6.5 mmol/l) | 11.77 (6.8–23.54) | 2.9–70.92 | 20.90 (11.55–39.31) | 7.20 (5.51–12.33) | < 0.0001* |
| SGOT (10–40 U/l) | 73.25 (43.40–104.60) | 13.2–852.2 | 81.75 (50.17–113.67) | 51.50 (35.95–104.1) | 0.0112* |
| SGPT (13–31 U/l) | 70.5 (41.03–112.7) | 18.20–2147 | 101.30 (64.32–161.80) | 53.15 (36.32–90.22) | 0.0045* |
| CRP < 0.5 mg/l | 180.2 (90.73–220.4) | 11.30–323.5 | 190.20 (153.30–225.10) | 152.80 (52.75–218.67) | 0.0176* |
| Serum bilirubin (5–21 µmol/l) | 19.07 (11.1–59.7) | 4.5–373.9 | 55.20 (18.26–164.21) | 12.26 (10.29–19.47) | 0.0003* |
*p < 0.05: Mann–Whitney U test
Fig. 2Comparison of serum TNF, IL-10 and sTNFR1 levels (pg/ml) in leptospirosis patients (n = 62) and healthy controls (n = 31). Expression of serum TNF, IL-10 and sTNFR1 in leptospirosis patients and healthy controls were determined by ELISA assays. a Serum TNF expression in patients with leptospirosis and healthy controls; a significantly elevated serum TNF expression (p = 0.0022) was observed among leptospirosis patients compared to healthy controls. b Serum IL-10 expression in patients with leptospirosis and healthy controls; a significantly elevated serum IL-10 expression (p < 0.0001) was observed in leptospirosis patients compared to healthy controls. c sTNFR1 expression in patients with leptospirosis and healthy controls; a significant suppression of sTNFR1 (p < 0.0001) were observed among leptospirosis patients compared to healthy controls
Serum concentrations of TNF, IL-10 and sTNFR1 for leptospirosis patients (n = 62) and healthy controls (n = 31)
| Median (range) | ||||||
|---|---|---|---|---|---|---|
| Healthy controls ( | Patients without complications ( | Patients with complications ( | Healthy-without complications | Healthy-with complications | Without and with complications | |
| TNF (pg/ml) | 35.94 (12.31–114.29) | 77.97 (15.48–3171.42) | 78.12 (20.06–334.95) | 0.0103* | 0.0349* | NS |
| IL-10 (pg/ml) | 11.86 (2.01–62.38) | 25.38 (5.83–195.84) | 90.66 (6.30–1167.97) | 0.0003* | < 0.0001* | 0.0011* |
| sTNFR1 (pg/ml) | 77.59 (17.47–218.94) | 18.56 (0–100.87) | 17.89 (0–110.52) | < 0.0001* | < 0.0001* | NS |
*p < 0.05: Mann–Whitney U test
NS Not significant
Serum concentrations of TNF, IL-10, sTNFR1, IL-10/TNF ratio and sTNFR1/TNF ratio among leptospirosis patients (n = 62) in relation to complications and day of fever
| Patients with complications ( | Patients without complications ( | |||||
|---|---|---|---|---|---|---|
| Fever day | Fever day | |||||
| ≤ 6 days ( | > 6 days ( | ≤ 6 days ( | > 6 days ( | |||
| IL-10 | 139.0 | 8.970 | < 0.0001* | 33.08 | 18.10 | 0.1101 |
| TNF | 85.27 | 33.47 | 0.1190 | 79.52 | 74.77 | 0.9807 |
| sTNFR1 | 17.80 | 18.44 | 0.8773 | 18.18 | 20.26 | 0.4825 |
| IL-10/TNF ratio | 2.231 | 0.3182 | 0.0050* | 0.5563 | 0.2788 | 0.2176 |
| sTNFR1/TNF ratio | 0.1898 | 0.7234 | 0.0760 | 0.07678 | 0.2681 | 0.5893 |
*p < 0.05: Mann–Whitney U test
Concentration of TNF with TNF polymorphisms among patients with leptospirosis
| Polymorphism | Genotype | Serum TNF (pg/ml) | |||
|---|---|---|---|---|---|
| Media | Range | ||||
| TNF − 238 | GG (wild type) | 49 | 72.7 (32.3–107.0) | 15.5–1171.0 | 0.1088 |
| GA (heterozygous) | 08 | 94.5 (82.9–198.2) | 73.2–277.6 | ||
| AA (mutated) | 05 | 79.4 (53.6–1794.3) | 39.1–3171.4 | ||
| TNF − 308 | GG (wild type) | 48 | 79.4 (41.2–135.2) | 15.5–1171.0 | 0.9482 |
| GA (heterozygous) | 14 | 73.57 (61.4–235.1) | 16.5–3171.4 | ||
| AA (mutated) | 00 | – | – | ||
| TNF − 863 | CC (wild type) | 37 | 81.0 (58.0–139.6) | 15.5–3171.4 | 0.5544 |
| CA (heterozygous) | 19 | 76.2 (31.4–207.4) | 16.5–417.1 | ||
| AA (mutated) | 06 | 69.8 (23.5–124.5) | 20.0–220.8 | ||
*p < 0.05: Kruskal–Wallis test